NVP-BHG712 is primarily utilized in research settings as a selective inhibitor of Ephrin type-B receptor 4 (EphB4), a receptor tyrosine kinase. Its application is significant in studying cancer biology, as EphB4 is implicated in tumor angiogenesis and progression. By inhibiting EphB4, NVP-BHG712 helps researchers explore its role in tumor growth, metastasis, and vascular development. This compound is also used to investigate potential therapeutic strategies targeting EphB4 in various cancers, including breast, ovarian, and colorectal cancers. Additionally, it aids in understanding the signaling pathways involved in cell proliferation, migration, and survival, contributing to the development of targeted cancer therapies.